Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
Swiss pharma firm Acino has acquired M8 Pharmaceuticals, a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil. 20 September 2023
US pharma major Eli Lilly has revealed it suing spas, wellness centers and compounding pharmacies selling unapproved and compounded versions of its type 2 diabetes drug Mounjaro (tirzepatide). 20 September 2023
A shortening cash runaway and a lack of near-term “value creation prospects” have forced some difficult decisions for Californian cancer firm Kinnate Biopharma. 20 September 2023
Germany’s Merck KGaA today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. 20 September 2023
The European Commission has authorized Apretude (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention, from ViiV Healthcare, the specialist HIV company majority-owned by UK Pharma major GSK. 19 September 2023
Japanese drug major Astellas Pharma announced positive 24-month top-line results from the Phase III GATHER2 clinical trial evaluating the efficacy and safety of Izervay (avacincaptad pegol intravitreal solution), a complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). 19 September 2023
The European Commission (EC) has approved Otsuka Pharmaceutical and its subsidiary Astex Pharmaceuticals’ Inaqovi (oral decitabine and cedazuridine) as monotherapy for the treatment of adults with newly-diagnosed acute myeloid leukemia (AML) who are ineligible for standard induction chemotherapy. 19 September 2023
A cancer drug under development by Cellectar Biosciences, a company based in New Jersey, USA, has been awarded an expedited review framework from the European Medicines Agency. 19 September 2023
Leading Indian drugmaker Sun Pharmaceutical Industries has entered into a license agreement with US privately-held biopharma Pharmazz to commercialize a first-in-class innovative drug, Tyvalzi (sovateltide) in India. 18 September 2023
Vaccines Europe - a specialized group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) - has issued a warning. 18 September 2023
UK-based lifecycle management and pharma manufacturing company Pharmanovia today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from French pharma major Sanofi. 18 September 2023
CSL Seqirus has unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal influenza on hospitals and broader healthcare systems. 18 September 2023
Just three months ago, the US Food and Drug Administration (FDA) extended the review period of the new drug application (NDA) for blood cancer drug momelotinib by three months to provide time to review recently submitted data. 18 September 2023
Significant changes to the way European health technology assessments (HTA) take place is underway, with a transitional period set to be in force for several years. 18 September 2023
The US Food and Drug Administration has approved updated labeling for Temodar (temozolomide), a legacy oncology drug developed by Merck & Co. 16 September 2023
Following its September 2023 meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended approval of six novel medicines. 15 September 2023
While legal challenges surrounding the implementation of the Inflation Reduction Act (IRA) continue to mount, the Centers for Medicare & Medicaid Services (CMS) has touted the success of the program. 15 September 2023
The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Quviviq (daridorexant) for adults in England and Wales with chronic insomnia. 15 September 2023
The MAPS Public Benefit Corporation - a subsidiary of the Multidisciplinary Association for Psychedelic Studies - appears to be moving ever closer to an attention-grabbing approval for MDMA (3,4-methylenedioxy-methamphetamine). 15 September 2023